The number of LAG-3 Positive (>=1%) participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized LAG-3 positive (>=1%) participants in each arm; recorded between randomization date and the date of objectively documented progression [per RECISIT 1.1], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.

CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions

All randomized LAG-3 positive (>=1%) participants

Objective response rate (ORR) based on Blinded Independent Central Review (BICR) and Investigator assessments is defined as the number of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized participants in each arm; recorded between randomization date and the date of objectively documented progression [per RECISIT 1.1], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.

CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions Progression=At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study and the sum must also demonstrate an absolute increase of at least 5 mm.

All randomized LAG-3 positive (>=1%) participants, and all randomized LAG-3 negative (<1%) participants, and all randomized participants

Duration of Response (DOR) based on Blinded Independent Central Review (BICR) and investigator is defined as the time between the date of first documented complete response (CR) or partial response (PR) and the date of the first disease progression, per RECIST 1.1, or death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.

CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions

All randomized responders with LAG-3 positive (>=1%), and all randomized responders with LAG-3 negative (<1%), and all randomized responders

Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.

All randomized LAG-3 positive (>=1%) participants, and all randomized LAG-3 negative (<1%) participants, and all randomized participants

Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) and Investigator is defined as the time between the date of randomization and the first date of documented progression, or death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. Participants who die without a reported prior progression (and die without start of subsequent therapy) will be considered to have progressed on the date of death.

Progression=At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study and the sum must also demonstrate an absolute increase of at least 5 mm.

All randomized LAG-3 positive (>=1%) participants, and all randomized LAG-3 negative (<1%) participants, and all randomized participants

Number of participants with any grade adverse events (AEs), serious adverse events (SAE), and adverse events leading to discontinuation using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v 5.0). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires inpatient hospitalization, results in significant disability, is a birth defect, or is an important medical event.

All treated participants

Number of participants who died in each arm.

All treated participants

Number of participants with laboratory abnormalities in specific liver tests based on US conventional units. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized:

• ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN
• Total bilirubin > 2 x ULN
• ALP > 1.5 x ULN
• Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN
• Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN
• Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN
• Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN

All treated participants with at least one on-treatment measurement of the corresponding laboratory parameter

Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized:

• TSH value > ULN and
• with baseline TSH value <= ULN
• with at least one FT3/FT4 test value < LLN within 2-week window after the abnormal TSH test
• with all FT3/FT4 test values >= LLN within 2-week window after the abnormal TSH test
• with FT3/FT4 missing within 2-week window after the abnormal TSH test.
• TSH < LLN and
• with baseline TSH value >= LLN
• with at least one FT3/FT4 test value > ULN within 2-week window after the abnormal TSH test
• with all FT3/FT4 test values <= ULN within 2-week window after the abnormal TSH test
• with FT3/FT4 missing within 2-week window after the abnormal TSH test

All treated participants with thyroid stimulating hormone (TSH) abnormality measurement

The number of LAG-3 Positive (>=1%) participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized LAG-3 positive (>=1%) participants in each arm; recorded between randomization date and the date of objectively documented progression [per RECISIT 1.1], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.

CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions Progression=At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study and the sum must also demonstrate an absolute increase of at least 5 mm.

All randomized LAG-3 positive (>=1%) participants